Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278102 | 0.78 | KMT2A (0.72) | KMT2AMEN1MAOBNPSR1MAPT | |
| SCHEMBL4273008 | 0.77 | KMT2A (0.62) | KMT2AMEN1MAOBATMNPSR1 | |
| SCHEMBL5140571 | 0.73 | KMT2A (0.72) | KMT2AMEN1MAOBNPSR1MAPT | |
| SCHEMBL4752752 | 0.72 | NPSR1 (0.68) | KMT2AMEN1MAOBATMNPSR1 | |
| SCHEMBL4273981 | 0.72 | KMT2A (0.62) | KMT2AMEN1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL13994872 | 0.71 | KMT2A (1.00) | KMT2AMEN1MAOBNPSR1MAPT | |
| SCHEMBL5624203 | 0.71 | KMT2A (0.70) | KMT2AMEN1MAOBNPSR1MAPT | |
| SCHEMBL15535815 | 0.70 | KCNN4 (0.51) | KMT2AMAPT | |
| SCHEMBL714233 | 0.70 | KCNN4 (0.51) | KMT2AMAPT | |
| SCHEMBL27545187 | 0.70 | KMT2A (0.74) | KMT2AMEN1MAOBNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | KMT2A 41/4885MEN1 1807/4885MAOB 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.